London
· Delayed Price · Currency is GBP · Price in SEK Hansa Biopharma AB Statistics
Total Valuation
Hansa Biopharma AB has a market cap or net worth of GBP 170.09 million. The enterprise value is 199.62 million.
| Market Cap | 170.09M |
| Enterprise Value | 199.62M |
Important Dates
The next estimated earnings date is Thursday, February 6, 2025.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +15.98% |
| Shares Change (QoQ) | +7.76% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 38.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.14 |
| EV / Sales | 14.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.88 |
Financial Position
The company has a current ratio of 2.45
| Current Ratio | 2.45 |
| Quick Ratio | 2.44 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.37 |
| Interest Coverage | -6.57 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -37.08% |
| Return on Invested Capital (ROIC) | -51.97% |
| Return on Capital Employed (ROCE) | -98.42% |
| Revenue Per Employee | 103,201 |
| Profits Per Employee | -356,795 |
| Employee Count | 168 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 34.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +144.64% in the last 52 weeks. The beta is 1.46, so Hansa Biopharma AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | +144.64% |
| 50-Day Moving Average | 32.90 |
| 200-Day Moving Average | 39.12 |
| Relative Strength Index (RSI) | 54.55 |
| Average Volume (20 Days) | 22,400 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hansa Biopharma AB had revenue of GBP 13.93 million and -48.17 million in losses. Loss per share was -0.82.
| Revenue | 13.93M |
| Gross Profit | 7.44M |
| Operating Income | -46.08M |
| Pretax Income | -48.14M |
| Net Income | -48.17M |
| EBITDA | -45.85M |
| EBIT | -46.08M |
| Loss Per Share | -0.82 |
Balance Sheet
The company has 40.72 million in cash and 70.56 million in debt, giving a net cash position of -29.84 million.
| Cash & Cash Equivalents | 40.72M |
| Total Debt | 70.56M |
| Net Cash | -29.84M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -23.54M |
| Book Value Per Share | -0.35 |
| Working Capital | 32.48M |
Cash Flow
In the last 12 months, operating cash flow was -51.50 million and capital expenditures 21,260, giving a free cash flow of -51.47 million.
| Operating Cash Flow | -51.50M |
| Capital Expenditures | 21,260 |
| Free Cash Flow | -51.47M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 53.43% |
| Operating Margin | -330.77% |
| Pretax Margin | -345.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Hansa Biopharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.98% |
| Shareholder Yield | -15.98% |
| Earnings Yield | -28.32% |
| FCF Yield | -30.26% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |